Contact the Editorial Desk

Editorial correspondence

Advantage Peptides welcomes correspondence on the research record: a citation quoted inaccurately, a newly published study on BPC-157 or its constituent peptides, or a regulatory update that changes an approval or scheduling status. This is the most useful class of message this desk receives, and each is read carefully.

The most actionable submissions specify the page in question, the exact passage being corrected or challenged, and the supporting reference — a PubMed identifier or full citation wherever possible. That format allows a proposed correction to be checked against its source before any change is made.

Editorial mailbox: editors@advantagepeptides.com

What this desk cannot do

Advantage Peptides is a literature digest, not a clinical service or product vendor, so it cannot advise on or recommend human use of any peptide discussed here; suggest a dose, schedule or route of administration for any individual; sell, source, or help locate any compound from any supplier; or evaluate whether a cited finding applies to a specific person's situation.

None of BPC-157, GLOW, or KLOW is an approved medicine, and none is legally available as a human pharmaceutical. Readers seeking guidance on tissue repair, tendon or ligament recovery, or any related condition should consult a licensed clinician. Athletes subject to anti-doping testing should be aware that some components discussed here intersect with WADA-monitored substances. Responses to editorial correspondence are not guaranteed and may be delayed.